作者: Dereck Amakye , Zainab Jagani , Marion Dorsch
DOI: 10.1038/NM.3389
关键词:
摘要: Major progress has been made in recent years the development of Hedgehog (Hh) pathway inhibitors for treatment patients with cancer. Promising clinical trial results have obtained cancers that harbor activating mutations Hh pathway, such as basal cell carcinoma and medulloblastoma. However, many cancers, which ligand overexpression is thought to drive tumor growth, disappointing. Here we review preclinical data continue shape our understanding tumorigenesis emerging experience smoothened inhibitors.